SGS expands testing capabilities at its Glasgow facility

29 Jan 2019

Clients will benefit from a fully comprehensive range of validated biosafety methods to support cell bank and viral vaccine manufacturing and lot release of drug product.

SGS has invested £7.6 million in its facility in Glasgow, UK to expand the capabilities and capacity for testing cell banks and routine bulk harvest for vaccines, gene and cell therapies, monoclonal antibodies and other recombinant protein-based biological medicines. The investment has been supported in part by a Scottish Enterprise Research and Development grant award of £1.7 million.

SGS expands testing capabilities at its Glasgow facility

The new laboratory has added an additional 1,200 m2 to the existing facility and will be adjacent to SGS’s existing global center of excellence for cell banks and viral vaccine biosafety.

The facility now totals 2,400 m2, employs 65 staff and plans to significantly increase the number of scientific and quality personnel at the site. Clients will benefit from a fully comprehensive range of validated biosafety methods to support cell bank and viral vaccine manufacturing and lot release of drug product, as well as new technologies for pathogen detection, including next-generation nucleic acid sequencing and new cell-based viral detection systems. The new laboratory will also increase the capacity of all existing biosafety services and enhanced real-time polymerase chain reaction (PCR) platforms, to support viral safety and genetic stability assessment of cell banks for vaccines, gene and cell therapies.

In addition, in accordance with the requirements of the US and European Pharmacopeia, SGS will undertake the development and validation of new cell-based viral detection systems at the site.

“As the pharmaceutical industry becomes increasingly focused on large molecule biologics, vaccines, gene and cell therapies, SGS continues to increase its service capacity and capabilities in this area,” commented Archie Lovatt, Scientific Director. “This is a rapidly expanding field, where much broader and highly specialized testing expertise and equipment are required to establish and ensure the safety of novel human therapies and vaccines, and one that SGS sees as key to its strategic growth.”

Julia Brown, Director for High Value Manufacturing and Health at Scottish Enterprise, added: “This investment from SGS is testament to the strength of our life sciences sector, as well as an endorsement of the wealth of talent and skills we have to offer. This expansion is great news for Scotland, creating further high-value employment in Glasgow, as well as positioning SGS Vitrology for future growth.”

Read More

Related news

Vetter's Skokie facility expansion nears completion

Vetter's Skokie facility expansion nears completion

17 Apr 2019

Expansions will help meet an increase in customer projects; a second extension is in the final planning stage.

Read more 
Catalent to acquire gene therapy leader Paragon Bioservices

Catalent to acquire gene therapy leader Paragon Bioservices

16 Apr 2019

Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare.

Read more 
Colorcon expands functional film coatings through the CR Alliance with DuPont

Colorcon expands functional film coatings through the CR Alliance with DuPont

15 Apr 2019

The Aquacoat product line provides modified release drug profiles with the added benefit of global regulatory acceptance.

Read more 
Hovione Technology acquires global rights to new pulmonary inhaler device

Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Read more 
Exploristics surges ahead with £1m investment

Exploristics surges ahead with £1m investment

15 Apr 2019

The loan will be used to develop KERUS Cloud - currently the only software that can simulate trials with multiple correlated outcomes - by integrating it into an intelligent software ecosystem.

Read more 
Catalent celebrates opening of second Shanghai facility

Catalent celebrates opening of second Shanghai facility

14 Apr 2019

Catalent’s two Shanghai locations will provide sponsors with an optimized supply solution for studies being undertaken in China, the Asia-Pacific region and globally.

Read more 
Global collaboration to innovate more natural and additive-free nutraceuticals

Global collaboration to innovate more natural and additive-free nutraceuticals

12 Apr 2019

Initiative will enable Sirio Pharma to keep abreast of regional trends, new ingredients, dosage forms and claims to provide customers unique product ideas for line extensions.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
New China-based biotechs fueling growth in manufacturing across China

New China-based biotechs fueling growth in manufacturing across China

9 Apr 2019

New guidelines will see poorer quality manufacturers drop out of the market.

Read more